Skip to main content
Premium Trial:

Request an Annual Quote

Progenitor and Cambridge Antibody Form Collaboration

Premium

MENLO PARK, Calif.--Progenitor, a developer of genomics drug leads, announced a collaboration agreement with Cambridge Antibody, a British biotech firm that holds technology for the rapid isolation of human monoclonal antibodies that has applications as a drug discovery tool in functional genomics. The two firms said the arrangement will allow them to accelerate their respective product development programs by sharing elements of each other's technologies. Progenitor will give Cambridge Antibody access to novel genes as targets for antibody-based therapeutics, and will get new antibody-based functional genomics tools to characterize gene discoveries from Cambridge Antibody.

Progenitor CEO Douglass Given said the collaboration expands his firm's functional genomics capabilities, "and provides an unprecedented opportunity to move numerous gene discoveries quickly through target validation and into drug development programs."

Filed under